Bio-Rad Laboratories, Inc.’s Stock Price Dips to $268.26, Recording a Negative 4.16% Shift

Bio-Rad Laboratories, Inc. (BIO)

268.26 USD -11.65 (-4.16%) Volume: 0.27M

Bio-Rad Laboratories, Inc.’s stock price stands at 268.26 USD, witnessing a dip of -4.16% this trading session with a trading volume of 0.27M, reflecting a negative YTD performance of -16.92%. An in-depth understanding of BIO’s stock performance for savvy investors.

Latest developments on Bio-Rad Laboratories, Inc.

Recent activities surrounding Bio-Rad Laboratories A have significantly influenced its stock price today. The company reported mixed Q1 2024 earnings, surpassing EPS estimates but missing revenue targets. Despite facing market challenges, Bio-Rad thrived on global sales and testing uptakes, and reiterated its 2024 revenue growth outlook. The launch of three StarBright Red Dyes and the expansion of its range of antibody markers have further bolstered its market position. However, the sale of 3,184 shares by Truist Financial Corp and the company’s oversold status have led to a slight dip in share prices.

Bio-Rad Laboratories, Inc. on Smartkarma

Analysts at Baptista Research have initiated coverage on Bio-Rad Laboratories A, a manufacturer of life science research and clinical diagnostic products. In their reports, they highlight the company’s resilience and potential for growth in the coming years. Despite a decrease in net sales in FY 2023, Bio-Rad Laboratories A shows promise for improvements and expansion.

Furthermore, Baptista Research delves into the impacts of global economic conditions and China’s new policies on Bio-Rad Laboratories A‘s market performance. The analysts point out varying performances across segments and discuss key issues such as the influence of Bio-pharma and challenges in China’s economic landscape. These insights provide investors with a comprehensive overview of the company’s position in the market.

A look at Bio-Rad Laboratories, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bio-Rad Laboratories A has a positive long-term outlook. The company scores high in the Value category, indicating that it offers good value for investors. However, its Dividend and Growth scores are lower, suggesting that it may not be the best choice for those seeking dividends or significant growth. In terms of Resilience and Momentum, Bio-Rad Laboratories A scores moderately, showing that it has some stability and positive market momentum.

Bio-Rad Laboratories, Inc. is a multinational company that specializes in life science research products, clinical diagnostics, and analytical instrumentation. The company’s products and systems are designed to separate complex chemical and biological materials, as well as identify, analyze, and purify their components. Overall, Bio-Rad Laboratories A shows promise for investors looking for value and a company with a solid foundation in the life sciences industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma